BioCentury | May 16, 2005
Finance

IPO angst in Europe

...The stock is flat from its IPO price. The other four - reproductive health play Ardana Bioscience Ltd....
BioCentury | Apr 25, 2005
Clinical News

EP-1572: Phase I data

...to develop and market EP-1572 in 2002. Aeterna Zentaris Inc. (TSE:AEZ; AEZS), Quebec City, Quebec Ardana Bioscience Ltd....
BioCentury | Apr 4, 2005
Finance

2Q Financial Market Preview: Steady but unsatisfying

...the three highest-profile IPOs showed that international investors also are giving push back on offerings. Ardana Bioscience Ltd....
BioCentury | Feb 21, 2005
Clinical News

Teverelix LA: Phase IIa data

...second set of 14 patients in the ongoing Phase IIa trial are expected next quarter. Ardana Bioscience Ltd....
BioCentury | Feb 7, 2005
Company News

Ardana Bioscience, U.K. Medical Research Council deal

...Human Reproductive Sciences Unit. The original deal began in 2000 and had a five-year term. Ardana Bioscience Ltd....
BioCentury | Nov 1, 2004
Clinical News

Striant SR testosterone regulatory update

...seek national marketing authorizations and expect to launch Striant in the second quarter of 2005. Ardana Bioscience Ltd....
BioCentury | Aug 9, 2004
Company News

Ardana Bioscience management update

Ardana Bioscience Ltd. , Edinburgh, U.K. Business: Genitourinary Hired: Time Morley as VP of preclinical sciences, formerly senior director of molecular and cellular pharmacology at Vernalis Research Ltd. WIR Staff Genitourinary...
BioCentury | Aug 9, 2004
Clinical News

Striant testosterone: Phase III data

...see BioCentury, June 24, 2002). Results were published the Journal of Clinical Endocrinology & Metabolism. Ardana Bioscience Ltd....
BioCentury | Jul 5, 2004
Clinical News

Striant SR regulatory update

...expects marketing authorization in EU countries over the next 12 months, beginning late this year. Ardana Bioscience Ltd....
BioCentury | Jun 7, 2004
Company News

Ardana Bioscience, Columbia sales and marketing update

...the U.K. to treat hypogonadism. Ardana has U.K. and European commercialization rights to the compound. Ardana Bioscience Ltd....
Items per page:
1 - 10 of 34
BioCentury | May 16, 2005
Finance

IPO angst in Europe

...The stock is flat from its IPO price. The other four - reproductive health play Ardana Bioscience Ltd....
BioCentury | Apr 25, 2005
Clinical News

EP-1572: Phase I data

...to develop and market EP-1572 in 2002. Aeterna Zentaris Inc. (TSE:AEZ; AEZS), Quebec City, Quebec Ardana Bioscience Ltd....
BioCentury | Apr 4, 2005
Finance

2Q Financial Market Preview: Steady but unsatisfying

...the three highest-profile IPOs showed that international investors also are giving push back on offerings. Ardana Bioscience Ltd....
BioCentury | Feb 21, 2005
Clinical News

Teverelix LA: Phase IIa data

...second set of 14 patients in the ongoing Phase IIa trial are expected next quarter. Ardana Bioscience Ltd....
BioCentury | Feb 7, 2005
Company News

Ardana Bioscience, U.K. Medical Research Council deal

...Human Reproductive Sciences Unit. The original deal began in 2000 and had a five-year term. Ardana Bioscience Ltd....
BioCentury | Nov 1, 2004
Clinical News

Striant SR testosterone regulatory update

...seek national marketing authorizations and expect to launch Striant in the second quarter of 2005. Ardana Bioscience Ltd....
BioCentury | Aug 9, 2004
Company News

Ardana Bioscience management update

Ardana Bioscience Ltd. , Edinburgh, U.K. Business: Genitourinary Hired: Time Morley as VP of preclinical sciences, formerly senior director of molecular and cellular pharmacology at Vernalis Research Ltd. WIR Staff Genitourinary...
BioCentury | Aug 9, 2004
Clinical News

Striant testosterone: Phase III data

...see BioCentury, June 24, 2002). Results were published the Journal of Clinical Endocrinology & Metabolism. Ardana Bioscience Ltd....
BioCentury | Jul 5, 2004
Clinical News

Striant SR regulatory update

...expects marketing authorization in EU countries over the next 12 months, beginning late this year. Ardana Bioscience Ltd....
BioCentury | Jun 7, 2004
Company News

Ardana Bioscience, Columbia sales and marketing update

...the U.K. to treat hypogonadism. Ardana has U.K. and European commercialization rights to the compound. Ardana Bioscience Ltd....
Items per page:
1 - 10 of 34